Medtronic in poor SHAPE
This article was originally published in The Gray Sheet
Executive Summary
Preliminary results of the firm's Screened Health Assessment and Pacer Evaluation trial randomizing patients who received implantable gastric stimulation therapy for the management of obesity against a placebo group failed to meet the efficacy endpoint of a 10 percentage-point difference in mean excess weight loss at one year, the firm announces Dec. 8. Medtronic says it is still committed to the technology and believes the SHAPE trial was influenced by unplanned treatment changes. The trial was initiated in May 2004 by Transneuronix, which Medtronic acquired in July 2005 (1"The Gray Sheet" July 4, 2005, p. 10)...
You may also be interested in...
Medtronic Launches Obesity Division With $260 Mil. Transneuronix Purchase
Transneuronix' Transcend gastric electrical stimulation device is the first product scheduled for commercialization by Medtronic's obesity management division
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.